Language
简体中文 
English GeticoFect 3000 Transfection Reagent
GeticoFect 3000 Transfection Reagent: Revolutionizing Transfection Efficiency1. Product OverviewGeticoFect 3000 Transfection Reagent, developed by Geneticsci Biotech (Shanghai) Co.
GeticoFect 3000 Transfection Reagent: Revolutionizing Transfection Efficiency1. Product OverviewGeticoFect 3000 Transfection Reagent, developed by Geneticsci Biotech (Shanghai) Co.
Catalog Number | Specification | Price (CNY) |
130101 | 0.75ml | 1,900.00 |
130102 | 1.5ml | 2,950.00 |
130103 | 15ml | 26,500.00 |
In the current era of booming biomedical research and biotechnology applications, cell transfection technology, as a key experimental tool, plays an indispensable role in numerous fields such as gene function research, drug development, and disease mechanism exploration. An excellent-performing transfection reagent is the core element for achieving efficient and accurate transfection. Developed against this backdrop, GeticoFect® 3000 Transfection Reagent brings a brand-new transfection experience to researchers with its advanced technology and outstanding performance.
GeticoFect® 3000 Transfection Reagent innovatively incorporates advanced nanoparticle technology, and the application of this technology is the core guarantee for its excellent performance. Nanoparticles possess unique physical and chemical properties—their tiny size and large specific surface area enable them to form stable and efficient complexes with exogenous nucleic acids (such as DNA, RNA, etc.). These complexes not only protect nucleic acids from degradation by intracellular nucleases but also cross cell membranes more effectively through special interactions with cell membranes, delivering nucleic acids accurately into cells.
In relevant applications, this advanced nanoparticle technology brings significant advantages. It can significantly improve the accuracy and reliability of experimental results, making the expression of exogenous genes in cells more stable and efficient. Meanwhile, due to the precise regulation of nanoparticle technology, the reproducibility of experiments has been greatly enhanced. Researchers can obtain similar and reliable transfection results in different experimental batches, laying a solid foundation for in-depth scientific research.
GeticoFect® 3000 Transfection Reagent boasts excellent transfection efficiency, thanks to the synergy between its unique formula and nanoparticle technology. After forming complexes with exogenous nucleic acids, the reagent can quickly recognize and bind to the cell surface, and promote the entry of complexes into cells through multiple mechanisms. For common cell lines:
• HEK293 cells: As a commonly used cell model in gene expression and protein production research, GeticoFect® 3000 can rapidly introduce exogenous genes into these cells for efficient expression.
• HeLa cells: A classic cell line in tumor research, the reagent can also efficiently complete the transfection process, providing strong support for the study of tumor-related genes.
• HL480 cells and other cell types: Efficient transfection can also be achieved, meeting the needs of different research fields.
Cytotoxicity is one of the important indicators for evaluating the performance of transfection reagents. During the design of GeticoFect® 3000 Transfection Reagent, full consideration was given to its impact on cells. By optimizing the composition and surface properties of nanoparticles, cytotoxicity has been reduced to an extremely low level. During transfection, the interaction between the reagent and cells is gentle, without significantly interfering with the normal physiological functions of cells. Cells can maintain high activity and proliferation ability after transfection, which is particularly important for experiments that require long-term culture and observation.
For example, in some cell signaling pathway studies, it is necessary to observe the signal changes of cells within a period of time after transfection. If the transfection reagent has high cytotoxicity, it may lead to cell death or functional abnormalities, thereby affecting the accuracy of experimental results. However, GeticoFect® 3000 Transfection Reagent can avoid these problems and ensure the smooth progress of experiments.
In addition to low cytotoxicity, GeticoFect® 3000 Transfection Reagent also has the characteristic of enhancing cell viability. This may be because certain components in the reagent can provide a certain degree of nutritional support for cells, or regulate the intracellular microenvironment to promote cell metabolism and growth. After transfection, cells have a more normal morphology and an accelerated proliferation rate, which helps improve the success rate of experiments and the reliability of data.
For instance, in stem cell research, cell viability and self-renewal ability are crucial. After transfection with GeticoFect® 3000 Transfection Reagent, stem cells can maintain good viability and pluripotent differentiation potential, providing a powerful tool for stem cell therapy and regenerative medicine research.
Many transfection reagents on the market often show poor performance when facing hard-to-transfect cells. However, GeticoFect® 3000 Transfection Reagent has been in-depth studied and optimized specifically for various hard-to-transfect cells. The R&D team adjusted the formula and surface modification of nanoparticles by analyzing the characteristics of hard-to-transfect cells (such as cell membrane structure, surface charge, and receptor distribution), enabling better interaction with these cells.
For example, due to their special physiological state and cell membrane structure, it is difficult for traditional transfection reagents to introduce exogenous nucleic acids into some primary cells. However, through the optimized nanoparticle technology, GeticoFect® 3000 Transfection Reagent can effectively overcome these obstacles and achieve efficient transfection of primary cells. This provides new possibilities for the research of primary cells, helping to gain a deeper understanding of cell physiological functions and disease mechanisms.
Compared with other competitors, GeticoFect® 3000 Transfection Reagent has lower cytotoxicity. Some traditional transfection reagents cause significant damage to cells during transfection, leading to a decrease in cell survival rate and even affecting the normal functions of cells. However, relying on its unique nanoparticle design and formula, GeticoFect® 3000 Transfection Reagent minimizes cell damage while ensuring efficient transfection. This allows researchers to focus more on research goals without worrying about the impact of cytotoxicity on experimental results.
GeticoFect® 3000 Transfection Reagent is suitable for transfection applications of DNA, RNA, and RNAi simultaneously. In gene research, different types of nucleic acids have different functions and application scenarios:
• DNA: Often used in experiments such as gene cloning, expression vector construction, and gene editing.
• RNA: Can be used for gene expression regulation and RNA function research.
• RNAi: An important gene silencing technology used to study gene functions and treat certain diseases.
GeticoFect® 3000 Transfection Reagent can meet the transfection needs of these different types of nucleic acids, providing researchers with a one-stop transfection solution. Whether it is the transfection of a single nucleic acid or the co-transfection of multiple nucleic acids, the reagent can show excellent performance.
Post-transfection handling is an important link in cell transfection experiments. Traditional transfection reagents usually require medium change after transfection to remove the potential impact of residual reagents on cells. However, medium change is not only cumbersome but also may cause certain damage to cells and increase the risk of experimental contamination.
Due to its low cytotoxicity and good biocompatibility, GeticoFect® 3000 Transfection Reagent does not require medium change after transfection. This greatly simplifies the experimental process, saves time and energy, and improves experimental efficiency. Researchers can devote more time and energy to the analysis and research of experimental results.
GeticoFect® 3000 Transfection Reagent has been deeply optimized for hard-to-transfect cell types, providing excellent transfection performance for a wide range of cell types. The cell types it can efficiently transfect are diverse, covering cell lines in multiple fields:
Fibroblasts are common connective tissue cells that play an important role in tissue repair, regeneration, and fibrosis.
• 3T3 cells: A commonly used mouse embryonic fibroblast line, often used in research on cell proliferation, differentiation, and signal transduction.
• COS-7 cells: An African green monkey kidney fibroblast line, widely used in gene expression and protein function research.
GeticoFect® 3000 Transfection Reagent can effectively introduce exogenous genes into these fibroblasts, providing strong support for related research. By transfecting specific genes, the functions and mechanisms of these genes in fibroblasts can be studied, laying a theoretical foundation for the development of tissue engineering and regenerative medicine.
Myoblasts are key cells for muscle development and regeneration.
• C2C12 cells: A mouse myoblast line, often used in research on muscle differentiation and muscle diseases.
• L6 CRL-1458 cells: Another myoblast line, with important research value in the fields of muscle biology and sports medicine.
GeticoFect® 3000 Transfection Reagent can efficiently deliver exogenous nucleic acids into myoblasts, promoting their differentiation and proliferation. By transfecting genes related to muscle development, the molecular mechanism of muscle development can be deeply understood, providing new ideas and methods for the treatment and rehabilitation of muscle diseases.
Hepatocytes are the main functional cells of the liver, playing important roles in substance metabolism, detoxification, and immunity.
• HepG2 cells: A human hepatocellular carcinoma cell line with some hepatocyte functions, often used in fields such as drug metabolism, liver toxicity, and liver cancer research.
• HuH7 cells: Another human hepatocellular carcinoma cell line, with important application value in hepatitis virus infection and liver cancer treatment research.
GeticoFect® 3000 Transfection Reagent provides an efficient transfection tool for gene research of hepatocytes. By transfecting genes related to liver diseases, the pathogenesis of liver diseases can be studied, and drugs for treating liver diseases can be screened, providing a theoretical basis for the prevention and treatment of liver diseases.
Erythroleukemia cells are a type of leukemia cell line, of great significance in the research on the pathogenesis and treatment of leukemia.
• K562 cells: A human erythroleukemia cell line, often used in research on cell biology, genetics, and drug treatment of leukemia.
GeticoFect® 3000 Transfection Reagent can meet the transfection needs of erythroleukemia cells. By transfecting genes related to leukemia, the pathogenesis of leukemia can be deeply understood, and new treatment strategies can be developed.
Lung cancer is one of the malignant tumors with high incidence and mortality worldwide.
• A549 cells: A human lung adenocarcinoma cell line, often used in research on the biological characteristics, metastasis mechanism, and drug treatment of lung cancer.
• NCI-H460 cells: Another human lung cancer cell line, with important application value in the molecular biology and clinical treatment research of lung cancer.
GeticoFect® 3000 Transfection Reagent provides reliable support for gene research of lung cancer cells. By transfecting genes related to the occurrence and development of lung cancer, the pathogenesis of lung cancer can be studied, and diagnostic markers and therapeutic targets for lung cancer can be screened, providing a theoretical basis for the early diagnosis and personalized treatment of lung cancer.
In addition, hundreds of other cell types (such as A549) can achieve efficient transfection with this reagent, fully demonstrating its wide applicability.
For many cell types, compared with other reagents, GeticoFect® 3000 Reagent has higher transfection efficiency and lower dosage. This means that under the condition of achieving the same transfection effect, using GeticoFect® 3000 Reagent can reduce reagent consumption, thereby bringing better economic cost-effectiveness to customers.
Taking the 1.5 mL specification product as an example, it is sufficient to complete up to 1500 transfection reactions (in 24-well plates). For scientific research laboratories and biotechnology enterprises, this greatly reduces experimental costs. Especially in large-scale experiments such as drug screening and gene library construction, it can significantly save reagent costs and improve resource utilization efficiency. At the same time, due to its high transfection efficiency and low cytotoxicity, the cost of repeated experiments caused by experimental failure is reduced, further improving economic benefits.
Cat. No. | Specification | Price(￥) |
130101 | 0.75ml | 1900.00 |
130102 | 1.5ml | 2950.00 |
130103 | 15ml | 26500.00 |
1. Q: What are the storage conditions for GeticoFect 3000 Transfection Reagent?
A: GeticoFect 3000 must be stored at 4°C; freezing is strictly prohibited. Freezing will destroy the structural integrity of lipid particles, leading to decreased reagent activity or even inactivation. Unopened reagents can be stably stored at 4°C for 18 months. After opening, the reagent should be kept refrigerated at 4°C, avoiding repeated removal to room temperature. It is recommended to use the opened reagent within 3 months to ensure optimal performance. In addition, the reagent can be stored at room temperature (20-25°C) for a short period (no more than 2 weeks), and accidental exposure to room temperature will not significantly affect its performance.
2. Q: What are the core advantages of GeticoFect 3000 compared with GeticoFect 2000?
A: As an upgraded version, GeticoFect 3000 has three core advantages:
• Wider cell compatibility: The transfection efficiency for hard-to-transfect cells (such as primary cells and stem cells) is 20%-30% higher than that of the 2000 series.
• Lower toxicity: Adopting a new lipid formula, the cell survival rate after transfection is increased by an average of more than 15%, making it particularly suitable for long-term experiments sensitive to cell viability.
• Stronger serum tolerance: The reagent can be directly diluted in serum-containing medium and form complexes without changing to serum-free medium, simplifying the operation process.
3. Q: When using GeticoFect 3000 for transfection, what is the optimal ratio range between DNA and the reagent? Do different nucleic acid types (DNA, siRNA, miRNA) require adjustment?
A: The recommended ratio range varies for different nucleic acid types:
• Plasmid DNA transfection: The ratio of DNA (μg) to GeticoFect 3000 (μL) is recommended to be 1:1.5-1:3.
• siRNA or miRNA transfection: Due to the higher binding efficiency between small-molecule nucleic acids and the reagent, the ratio can be adjusted to 1:1-1:2.
Specific optimization is required according to cell types. For example, a ratio of 1:2 works well for HEK293 cells when transfecting DNA, while primary neuron cells may require a ratio of 1:2.5-1:3 to balance efficiency and toxicity.
4. Q: How long after transfection can the expression of the target gene be detected? Is it related to cell types?
A: The detection time after transfection is closely related to cell types:
• Rapidly proliferating cells (e.g., HEK293, HeLa): The expression of the target gene can be detected 24-48 hours after DNA transfection, and the peak is reached at 48-72 hours.
• Primary cells or slow-growing cells (e.g., nerve cells): Obvious expression may take 48-72 hours, and the peak may be delayed to 72-96 hours.
For siRNA transfection, target gene silencing effects can be observed in most cells within 24-48 hours, and the optimal detection time is 48-72 hours.
5. Q: When cell death occurs after transfection with GeticoFect 3000, what are the possible causes and how to solve them?
A: Possible causes and solutions are as follows:
• Excessive reagent ratio: Reduce the ratio of DNA to reagent (e.g., from 1:3 to 1:2).
• Low cell density: For adherent cells, the confluency during transfection is recommended to be maintained at 70%-90%; for suspension cells, the density should not be less than 1×10⁶ cells/mL.
• Prolonged complex incubation time: Incubation for 4-6 hours is sufficient for ordinary cells; for sensitive cells, the medium can be changed after shortening the incubation time to 3-4 hours.
• Poor DNA quality (e.g., high endotoxin): Re-prepare nucleic acids using an endotoxin-free plasmid extraction kit.
6. Q: Can GeticoFect 3000 be used for co-transfection (e.g., co-transfection of DNA and siRNA)? What precautions should be taken during operation?
A: Yes, it can be used for co-transfection. Precautions include:
• Optimize the ratio of the two nucleic acids to the reagent separately. For example, prepare DNA at a ratio of 1:2 and siRNA at a ratio of 1:1.5, then mix to form complexes.
• The total amount of nucleic acids should not be too high to avoid increasing the cell burden. Generally, the total nucleic acid amount per well (6-well plate) should not exceed 4μg.
• When preparing complexes, first mix and dilute DNA and siRNA, then add diluted GeticoFect 3000 to avoid competition caused by the two nucleic acids binding to the reagent separately.
• It is recommended to extend the detection time after co-transfection (e.g., delay the detection of DNA expression to 72 hours) to ensure both nucleic acids play their roles.
7. Q: Can antibiotics be used during transfection? Why?
A: It is not recommended to use antibiotics during transfection. Antibiotics (such as penicillin, streptomycin, or gentamicin) commonly added to cell culture media can interact with GeticoFect® 3000 and its nucleic acid complexes, leading to two key issues:
Reduced transfection efficiency: Antibiotics may disrupt the structural stability of lipid nanoparticles in the reagent, preventing them from forming stable complexes with nucleic acids. This weakens the reagent’s ability to deliver nucleic acids into cells, resulting in lower transfection rates.
Increased cytotoxicity: Transfection temporarily makes cells more permeable and sensitive to external stress. Antibiotics, which are inherently toxic to prokaryotes, can exert unexpected toxic effects on transfected eukaryotic cells under these conditions, leading to higher cell death rates and compromised experimental results.
If antibiotic use is unavoidable (e.g., to prevent contamination in long-term cultures), we recommend:
Omitting antibiotics from the medium during transfection (replace with fresh, antibiotic-free medium 1–2 hours before adding complexes).
Adding antibiotics back to the medium 24–48 hours post-transfection, once cells have recovered from the transfection process and the complexes have been internalized.
8.Q: Is GeticoFect® 3000 suitable for large-scale transfection (e.g., shake flasks, bioreactors) for recombinant protein production? What are the key scaling-up considerations?
A: Yes, it supports reliable scaling from laboratory-scale (96-well plates) to industrial-scale (100 L+ bioreactors) for recombinant protein production. Key considerations for scaling-up include:
Ratio consistency: Maintain the same reagent-to-nucleic acid ratio validated in small-scale experiments. For example, if a 1:2 (μg DNA:μL reagent) ratio works for HEK293 cells in a 24-well plate, use the same ratio for 10 L suspension cultures (e.g., 100 mg DNA + 200 mL reagent).
Complex preparation: For large volumes, prepare complexes in a sterile, stirred vessel (with low-shear mixing) to ensure uniform distribution. Dilute nucleic acids in 5–10% of the total culture volume (using serum-free medium) first, then add the reagent dropwise while stirring at 50–100 rpm. Incubate for 15–20 minutes to allow complex formation before adding to the bioreactor.
Cell density: For suspension cells (e.g., HEK293F), maintain a density of 2–3 × 10⁶ cells/mL at transfection; for adherent cells on microcarriers, ensure 60–70% confluency on carriers to maximize contact with complexes.
Post-transfection feeding: Add cell culture supplements (e.g., glucose, glutamine, or chemically defined feeds) 24–48 hours post-transfection to extend the protein expression phase. This can increase yields of secreted proteins by 30–50% compared to non-fed cultures.
9• Q: Does GeticoFect® 3000 interfere with downstream experiments such as Western blotting, flow cytometry, or qPCR?
A: No, it has minimal interference with common downstream assays, thanks to its biodegradable lipid components and low residual levels in cells. Specific recommendations for key experiments:
Western blotting: The reagent does not bind to proteins or interfere with SDS-PAGE separation. Use standard protein extraction protocols (e.g., RIPA buffer) without additional purification—residual lipids are removed during sample preparation (e.g., centrifugation to clear cell lysates).
Flow cytometry: For intracellular staining (e.g., for target protein detection), fix cells with 4% paraformaldehyde 48–72 hours post-transfection. Residual reagent does not affect antibody binding or fluorescent signal intensity. For live cell sorting, wash cells once with PBS to remove free complexes before analysis.
qPCR: Lipid components do not inhibit Taq polymerase activity. For nucleic acid extraction (DNA/RNA), use commercial kits (e.g., Qiagen DNeasy® or RNeasy® Kits)—residual reagent is eliminated during column washing, ensuring accurate quantification of target genes.
10• Q: Can GeticoFect® 3000 be used for transfection of primary cells? Which primary cell types have been validated, and what special protocols are needed?
A: Yes, it is well-suited for primary cell transfection, with validated performance in several key types:
Primary neurons (e.g., mouse cortical or hippocampal neurons): Transfection efficiency reaches 35–45%, with cell survival >80% 72 hours post-transfection. Use a slightly higher reagent-to-DNA ratio (1:2.5–1:3) and add 1% BSA to the medium to enhance cell adhesion.
Primary hepatocytes (human/rat): Maintains liver-specific functions (e.g., albumin secretion) while achieving 30–40% transfection efficiency. Culture cells on collagen-coated plates and reduce the reagent volume by 10% to minimize toxicity.
Primary fibroblasts (human dermal/mouse embryonic): Transfection efficiency >50% with a 1:2 ratio. Use early passage cells (P0–P2) to ensure high viability.
Special protocols for primary cells:
Use low-passage cells (P0–P2) to avoid senescence-related transfection resistance.
Pre-incubate cells in serum-containing medium for 24 hours before transfection to allow attachment and recovery.
Avoid overconfluency (maintain 50–60% confluency for adherent primary cells) to ensure uniform complex contact.
11• Q: What is the maximum culture volume that GeticoFect® 3000 can support? Are there differences in performance between adherent and suspension cell cultures?
A: It supports culture volumes ranging from 100 μL (96-well plates) to 200 L (industrial bioreactors) with consistent performance. Key differences between adherent and suspension cultures:
Adherent cells: Optimal for small-to-medium scales (e.g., 6-well plates to T175 flasks). Ensure 70–80% confluency at transfection to maximize complex-cell contact. No medium change is needed post-transfection.
Suspension cells: Ideal for large-scale production (shake flasks to bioreactors). Maintain a density of 1–3 × 10⁶ cells/mL at transfection and use orbital shaking (120–150 rpm) to ensure uniform complex distribution.
In both culture types, the reagent’s performance (transfection efficiency, cytotoxicity) remains consistent as long as the reagent-to-nucleic acid ratio and cell density are maintained.
12• Q: What should I do if transfection efficiency is lower than expected, even after following the standard protocol?
A: Troubleshoot using the following steps:
Check cell quality: Ensure cells are in the logarithmic growth phase (viability >90%) and not overpassaged (limit to <20 passages for cell lines). Overconfluent or senescent cells have reduced uptake of complexes.
Validate nucleic acid quality: Use a spectrophotometer to confirm DNA purity (A260/A280 = 1.8–2.0) and agarose gel electrophoresis to check for degradation. High endotoxin levels (>0.1 EU/μg DNA) can reduce efficiency—re-purify DNA with an endotoxin-free kit.
Optimize the reagent-to-nucleic acid ratio: Test 3–4 ratios (e.g., 1:1.5, 1:2, 1:2.5, 1:3) to find the optimal balance. For example, HEK293 cells may perform best at 1:2, while HeLa cells may require 1:2.5.
Adjust complex incubation time: Incubate complexes at room temperature for 15–20 minutes—too short ( <10 minutes) leads to incomplete complex formation, while too long ( >30 minutes) causes particle aggregation.
Check medium components: Avoid media with high concentrations of polyamines, heparin, or divalent cations (Ca²⁺, Mg²⁺ > 2 mM), which disrupt complex stability. Switch to a standard medium (e.g., DMEM, Opti-MEM™) for transfection if needed.
